Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain

Summary

Venous thromboembolism (VTE) has a significant impact on healthcare costs but is largely preventable with anticoagulant prophylaxis using low-molecular-weight heparins (LMWHs), such as enoxaparin or dalteparin. Rivaroxaban and dabigatran etexilate are two new oral anticoagulants (NOACs) both compared with enoxaparin in separate trials. A decision analytic model with a healthcare and national payer perspective over a five-year time horizon was used to evaluate the cost-effectiveness of the NOACs for VTE prophylaxis after total hip replacement (THR) or total knee replacement (TKR) in France, Italy and Spain. Efficacy and safety data were obtained from randomised controlled trials of rivaroxaban vs enoxaparin and an indirect statistical comparison for rivaroxaban vs dabigatran. Rivaroxaban demonstrated dominance across all comparisons, indications and countries. In THR, total per-patient costs were reduced by up to €160 in the enoxaparin comparison and €115 in the dabigatran comparison, respectively. In addition, quality-adjusted life-years (QALYs) were increased by up to 0.0011 and 0.0012 in each comparison, respectively. Similarly, total costs were reduced in TKR by up to €137 and €28 in the enoxaparin and dabigatran comparisons, respectively. The total number of QALYs was increased by up to 0.0014 in the enoxaparin comparison and 0.0005 in the dabigatran comparison. The results were driven by costs since the incremental benefits were minimal. Rivaroxaban use could result in substantial healthcare cost savings and improved quality of life. The results are applicable across three European countries with differing healthcare systems so, potentially, could be generalised to a much wider population.

keywords

Cost-effectiveness - quality of life - orthopaedic surgery - rivaroxaban - venous thromboembolism

• References

• 1 National Clinical Guideline Centre - Acute and Chronic Conditions. Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, 2010. Available at: http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf. Accessed January 18 2012
• 2 Cowell CW. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty. Orthopedics 2009; 32: 67-73.
• 3 Imberti D, Bianchi C, Zambon A. et al. Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 2012; 7: 243-249.
• 4 OECD. Health at a Glance: Europe 2010. Available at: http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2010_health_glance-2010-en. Accessed August 8 2011
• 5 Bäckman K, Carlsson P, Kentson M. et al. Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment. Scand J Prim Health Care 2004; 22: 44-49.
• 6 Levy E, Gabriel S, Dinet J. et al. Assessing the total cost of management of a patient with deep vein thrombosis (DVT) in France and Italy. Value Health 2001; 4: 102-103.
• 7 Guijarro R, Montes J, San Román C. et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011; 105: 610-615.
• 8 Monreal M, Peidro L, Resines C. et al. Limited diagnostic workup for deep vein thrombosis after major joint surgery: findings from a prospective, multicentre, cohort study. Thromb Haemost 2008; 99: 1112-1115.
• 9 Bergqvist D. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics 2002; 20: 225-243.
• 10 Menzin J, Colditz GA, Regan MM. et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-764.
• 11 Saunders ME, Grant RE. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc 1998; 90: 677-680.
• 12 Diamantopoulos A, Lees M, Wells PS. et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010; 104: 760-770.
• 13 LeReun C, Wells P, Diamantopoulos A. et al. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ 2011; 14: 238-244.
• 14 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
• 15 Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
• 16 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
• 17 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
• 18 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
• 19 RE-MOBILIZE Writing Committee. Ginsberg JS, Davidson BL. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
• 20 Sullivan SD, Kahn SR, Davidson BL. et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003; 21: 477-496.
• 21 Quinlan DJ, Eikelboom JW, Dahl OE. et al. Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007; 5: 1438-1443.
• 22 White RH, Romano PS, Zhou H. et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
• 23 Prandoni P, Villalta S, Bagatella P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-428.
• 24 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
• 25 Nuijten MJ, Villar FA, Kosa J. et al. Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health 2003; 6: 126-136.
• 26 Galie N, Torbicki A, Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
• 27 Wlodarczyk JH, Cleland LG, Keogh AM. et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics 2006; 24: 903-915.
• 28 Ministry of Health. National DRG tariff (Ministry of Health Decree 18–10–2012; Official Gazette n. 23 28–01–2013).
• 29 Ministry of Health. Outpatient national tariffs (Ministry of Health Decree 18–10–2012; Official Gazette n. 23 28–01–2013)
• 30 Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l’Italia. Farmeconomia e percorsi terapeutici 2010; 11: 91-101.
• 31 Agenzia Farmaco. 2008 Available at: http://www.agenziafarmaco.gov.it/sites/default/files/classe_a_pubblic290208.pdf. Accessed September 21 2012
• 32 Compendio Farmaceutico - Farmadati. Accessed March 21, 2013 (BHC, data on file).
• 33 Honorato J, Gomez-Outes A, Navarro-Quilis A. et al. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 2004; 22: 885-894.
• 34 Gisber R, Brosa M. Base de Datos de Costes Sanitarios eSalud. Oblikue Consulting 2008. Available at: http://www.oblikue.com/bddcostes. Accessed May 11 2011
• 35 General Spanish Council of Pharmacist. Database of Medicines (2012). Available at: http://www.portalfarma.com. Accessed June 4 2013
• 36 Monreal M. (Coordinator) Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (R.I.E.T.E. Registry). Available at: http://www.riete.org. Accessed May 11 2011
• 37 Páramo JA, Feliu J, Iglesias R. et al. Profilaxis del tromboembolismo venoso: recomendaciones en pacientes médicos y sistema de alarma electrónica en pacientes hospitalizados. Rev Med Univ Navarra 2006; 50: 17-23.
• 38 Ministry of Health (Ministerio de Sanidad y Consumo), 2005. Available at: http://www.msc.es/estadEstudios/estadisticas/docs/NormaGRD2010/NORMA_2010_AP_GRD_V25_TOTAL_SNS.pdf. Accessed May 11 2011
• 39 l’Assurance Maladie. Available at http://www.codage.ext.cnamts.fr. Access March 15 2013
• 40 Agence Technique de l’Information sur l’Hospitalisation. Available at: http://www.atih.sante.fr. Accessed March 15 2013
• 41 l’Assurance Maladie. Fichier des GHS (version 19 - mars 2013). Availabe at: http://www.ameli.fr/l-assurance-maladie/documentation-technique/t2a-ccam-et-lpp/fichier-des-ghs-version-19-mars-2013.php. Accessed March 15 2013
• 42 Programme médicalisé des systèmes d’information (PMSI). Available at: http://stats.atih.sante.fr/mco/statghmmco.php. Accessed July 25 2011
• 43 Sungher DK, Folkerts K, McDonald H. et al. Venous thromboembolism: A Systematic Literature Review to identify multi-attribute utility values for use in economic models. Presented at ISPOR 15th Annual European Congress. Berlin, Germany: November 2012. abstract no. 31685.
• 44 National Institute for Health and Clinical Excellence. Clinical guidelines, CG92. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, 2010. Available at: http://guidance.nice.org.uk/CG92. Accessed May 17 2013
• 45 Highland KB, Strange C, Mazur J. et al. Treatment of pulmonary arterial hypertension: A preliminary decision analysis. Chest 2003; 124: 2087-2092.
• 46 Savoia E, Fantini MP, Pandolfi PP. et al. Assessing the construct validity of the Italian version of the EQ-5D: preliminary results from a cross-sectional study in North Italy. Health Qual Life Outcomes 2006; 4: 47
• 47 López-Bastida J, Oliva J, Antoñanzas F. et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010 April 20. Available at: http://www.ispor.org/regional_chapters/Spain/documents/Spanish-recommendations-on-economic-evaluation.pdf. Accessed May 17 2013
• 48 Capri S, Ceci A, Terranova L. et al. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inform J. 2001 35. 189-201. Available at: http://www.ispor.org/PEguidelines/source/Italy%20PE%20guidelines_Italy.pdf. Accessed May 17 2013
• 49 McCullagh L, Tilson L, Walsh C. et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27: 829-846.
• 50 Weitz JI. Unanswered questions in venous thromboembolism. Thromb Res 2009; 123 (Suppl. 04) S2-10.